Stanniocalcin-2 expression in glioblastoma – A novel prognostic biomarker: An observational study

Author:

Aydin Asim Armagan1ORCID,Yildirim Senay2ORCID

Affiliation:

1. Department of Clinical Oncology, Health Science University Antalya Training and Research Hospital, Antalya, Turkey

2. Department of Pathology, Health Science University Antalya Training and Research Hospital, Antalya, Turkey.

Abstract

The objective of this study was to assess the prognostic relevance of Stanniocalcin-2 (STC2) expression, as determined via immunohistochemistry in tumor tissue, in a cohort of 83 patients diagnosed with glioblastoma who underwent maximal safe surgical resection followed by radiotherapy concurrent with adjuvant temozolomide. STC2 expression levels were categorized using a 3-tiered semiquantitative system: negative expression (level 0−), low expression (level 1+), and high expression (levels 2 + and 3+). Patients were categorized into 2 distinct groups according to their STC2 expression levels: negative STC2 (−/+) and positive STC2 (++/+++). The primary outcome measure was the relationship between STC2 expression and progression-free survival (PFS), with overall survival (OS) serving as the secondary endpoint. Kaplan–Meier survival analysis confirmed that patients exhibiting high STC2 expression had significantly shorter OS (8 vs 20 months, P < .001) and PFS (6 vs 18 months, P < .001) than those with low or negative STC2 expression. Multivariate analysis revealed that STC2 expression was an independent prognostic factor for both OS (hazard ratio: 0.4; 95% confidence interval: 0.2–0.8; P < .05) and PFS (hazard ratio: 0.3; 95% confidence interval: 0.2–0.4; P < .05) in patients with glioblastoma. Furthermore, elevated STC2 expression in GBM was correlated with several established aggressive clinicopathological characteristics, including advanced age (≥65 years), low ECOG PS (≥2), and isocitrate dehydrogenase mutation negativity. These findings underscore that heightened STC2 expression within the tumor tissue of GBM patients functions as an adverse prognostic marker, correlating with an elevated risk of progression and reduced OS. Therapeutic interventions targeting the AKT-mTOR, ERK1-2, and mitogen-activated protein kinase pathways as well as immune checkpoint inhibitors and vascular endothelial growth factor blockade, as well as potential forthcoming antibody–drug conjugates targeting the STC2 molecule, have the potential to broaden the scope of combined treatment strategies.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference30 articles.

1. Management of glioblastoma: state of the art and future directions.;Tan;CA Cancer J Clin,2020

2. Rising incidence of glioblastoma multiforme in a well-defined population.;Grech;Cureus,2020

3. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017.;Ostrom;Neuro Oncol,2020

4. NCCN Guidelines: Central Nervous System Cancers Version 1.2024

5. Key clinical principles in the management of glioblastoma.;Kotecha;JCO Oncol Pract,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3